These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 22206766)

  • 1. Rehabilitation and multiple sclerosis: hot topics in the preservation of physical functioning.
    Dalgas U
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S43-7. PubMed ID: 22206766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Physical rehabilitation in multiple sclerosis: general principles and high-tech approaches].
    Peresedova AV; Chernikova LA; Zavalishin IA
    Vestn Ross Akad Med Nauk; 2013; (10):14-21. PubMed ID: 24640715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosis.
    Fernandez O; Berger T; Hartung HP; Putzki N
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):649-65. PubMed ID: 23146002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robotic-assisted step training (lokomat) not superior to equal intensity of over-ground rehabilitation in patients with multiple sclerosis.
    Vaney C; Gattlen B; Lugon-Moulin V; Meichtry A; Hausammann R; Foinant D; Anchisi-Bellwald AM; Palaci C; Hilfiker R
    Neurorehabil Neural Repair; 2012; 26(3):212-21. PubMed ID: 22140197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapies for mobility disability in persons with multiple sclerosis.
    Baird JF; Sandroff BM; Motl RW
    Expert Rev Neurother; 2018 Jun; 18(6):493-502. PubMed ID: 29772185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release fampridine for symptomatic treatment of multiple sclerosis.
    Korenke AR; Rivey MP; Allington DR
    Ann Pharmacother; 2008 Oct; 42(10):1458-65. PubMed ID: 18780812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.
    Tarakci E; Yeldan I; Huseyinsinoglu BE; Zenginler Y; Eraksoy M
    Clin Rehabil; 2013 Sep; 27(9):813-22. PubMed ID: 23543341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.
    Panitch H; Applebee A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1511-21. PubMed ID: 21635193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does robot-assisted gait training ameliorate gait abnormalities in multiple sclerosis? A pilot randomized-control trial.
    Straudi S; Benedetti MG; Venturini E; Manca M; Foti C; Basaglia N
    NeuroRehabilitation; 2013; 33(4):555-63. PubMed ID: 24018369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise and rehabilitation for individuals with multiple sclerosis.
    Brown TR; Kraft GH
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):513-55. PubMed ID: 15893685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK; Sorensen PS
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
    Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
    Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [DGRW-update: neurology--from empirical strategies towards evidence based interventions].
    Schupp W
    Rehabilitation (Stuttg); 2011 Dec; 50(6):354-62. PubMed ID: 22134865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fampridine and multiple sclerosis].
    Mathiesen HK; Sørensen PS
    Ugeskr Laeger; 2014 Jan; 176(3A):V06130416. PubMed ID: 25347174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What components of rehabilitation are helpful from the perspective of individuals with multiple sclerosis?
    Salminen AL; Kanelisto KJ; Karhula ME
    Disabil Rehabil; 2014; 36(23):1983-9. PubMed ID: 24506664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of high-tone power therapy on the functional status of patients with multiple sclerosis].
    Kubsik A; Klimkiewicz P; Klimkiewicz R; Jankowska K; Jankowska A; Woldańska-Okońska M
    Pol Merkur Lekarski; 2014 Jul; 37(217):24-9. PubMed ID: 25154195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.